Control of hyperphosphataemia in adult patients on haemodialysis or peritoneal dialysis, or w/ chronic kidney disease not on dialysis w/ serum P ≥1.78 mmol/L. Use in multiple therapeutic approach to control the development of renal bone disease.
Patients w/ serum P levels >2.42 mmol/L Total daily dose: 4.8 g to be taken over 3 meals/day; 1.78-2.42 mmol/L Total daily dose: 2.4 g to be taken over 3 meals/day.
Patient w/ chronic kidney disease not on dialysis w/ serum P level <1.78 mmol/L. Dysphagia; swallowing disorders; severe GI motility disorders; active inflammatory bowel disease, major GIT surgery. Intestinal obstruction & ileus/subileus. Peritonitis. Assess regularly serum vit A, D, E & K status. Possible folate deficiency. Metabolic acidosis. Hypocalcaemia/hypercalcaemia. Hypothyroidsim. Not indicated for control of hyperparathyroidism. Long-term chronic treatment. Pregnancy & lactation. Childn <18 yr.
Decreased bioavailability of ciprofloxacin. Reduced levels of ciclosporin, mycophenolate mofetil & tacrolimus. Very rare cases of hypothyroidism in combination w/ levothyroxine. Very rare cases of increased phosphate levels w/ proton pump inhibitors.
Sign Out
